MADRID, November 15, 2017 /PRNewswire/ --
PharmaMar (MCE:PHM) has announced today that the Independent Data Monitoring Committee (IDMC) has notified the Company of its recommendation that the Phase III (ATLANTIS) trial currently under way with Zepsyre® (PM1183) in combination with doxorubicin in small-cell lung cancer patients should continue without any changes.
The IDMC's recommendation came after an analysis of the safety data obtained with the first 150 patients treated in the trial. This pivotal randomised Phase III trial assesses the efficacy of PM1183 in combination compared with the standard treatment for this indication: investigator's choice of either Topotecan or CAV (cyclophosphamide, doxorubicin, and vincristine). The trial is expected to enroll approximately 600 patients and over half are already included.
Zepsyre® is a compound under clinical investigation. It is an inhibitor of RNA polymerase II. This enzyme is involved in the transcription process that is over-activated in tumors with transcription addiction. The antitumor efficacy of lurbinectedin is being investigated in various types of solid tumors, including a Phase III study for platinum-resistant ovarian cancer, a Phase II study for BRCA 1 and BRCA 2-associated metastatic breast cancer and a Phase III study for small cell lung cancer.
Headquartered in Madrid, PharmaMar is a leading biopharmaceutical company in the discovery and development of innovative marine-derived anticancer drugs. The company has a pipeline of drug candidates and a robust R&D oncology program. PharmaMar develops and commercializes YONDELIS® in Europe and has other clinical-stage programs under development for several types of solid and hematological cancers, Zepsyre® (PM1183), plitidepsin, PM184 and PM14. PharmaMar is a global biopharmaceutical company with subsidiaries in Germany, Italy, France, Switzerland, United Kingdom, Belgium, Austria and the United States. PharmaMar fully owns other companies: GENOMICA, a leading molecular diagnostics company; Sylentis, dedicated to researching therapeutic applications of gene silencing (RNAi); and two other chemical enterprises, Zelnova Zeltia and Xylazel. To learn more about PharmaMar, please visit us at http://www.pharmamar.com.
Media Contacts: Media Relations +34-638-79-62-15 and Investor Relations +34-914-444-500